Target residual moisture content for lyophilized drug products
By controlling the shelf temperature and vacuum pressure of the freeze-dryer and adopting a controlled drying process, the problem of insufficient stability of the biopharmaceutical formulation at room temperature is solved, and the long-term stability of the freeze-dried product and the refrigeration storage stability are achieved.
Patent Information
- Application Number
- CN202180012726.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-02-04
- Filing Date
- 2021-02-04
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2041-02-04
AI Technical Summary
The existing lyophilization methods are insufficient in the long-term storage of biopharmaceutical formulations, especially when it is difficult to maintain the stability of the product at room temperature, and the refrigerated storage conditions are unreliable in some places.
By controlling the shelf temperature and vacuum pressure of the freeze dryer, the controlled preliminary drying and secondary drying process is adopted to extend the secondary drying time to achieve the target residual moisture percentage, ensuring long-term stability or improvement of the freeze-dried product at room temperature. Refrigerated storage stability.
The long-term stability of the lyophilized product at room temperature and improved refrigeration storage stability are achieved, the product collapse and back-thawing are avoided, and the structural integrity and stability of the lyophilized cake is ensured.
Smart Images

Figure CN115151772B_ABST
Abstract
Description
[0001] The present application generally relates to methods for lyophilization of protein formulations. In particular, the present application provides lyophilization methods for achieving a target percentage of residual moisture for a lyophilized drug product that is stable for room temperature storage or has improved refrigerated storage stability. Background Art
[0002] Most biopharmaceutical formulations are unstable for long-term storage in solution due to various forms of degradation, aggregation or chemical modification. Lyophilization, e.g., freeze drying under controlled conditions, is a preferred method for converting biopharmaceutical formulations (e.g., protein formulations) to a solid state to improve the long-term storage stability of the product. The lyophilized product, e.g., cake, is preferably stored at about 2-8° C. and / or room temperature for a relatively long period of time. It may also be desirable for the cake to have a longer storage stability at room temperature to eliminate the need for refrigeration of late-stage protein drugs during commercial transportation and storage around the world, especially in places where electricity and refrigeration may be unreliable.
[0003] Lyophilization is a relatively expensive process that requires long processing times. The main goals of optimizing the lyophilization process can include: optimizing the process without risking product collapse; determining the apparent endpoint of primary drying; and optimizing secondary drying to achieve the desired residual moisture content of the lyophilized product. Optimization of the lyophilization cycle for a given biopharmaceutical formulation requires a balanced understanding of the lyophilization process, formulation characteristics, equipment capacity, and the actual risks associated with the process parameters. (Chang et al., 2004, American Association of Pharmaceutical Scientists, pp. 113-138, Freezing-drying process development for protein pharmaceuticals, Lyophilization of Biopharmaceuticals)
[0004] It will be appreciated that a need exists for a lyophilization process that can produce a lyophilized product having long-term room temperature storage stability or having improved refrigerated storage stability. Summary of the invention
[0005] Freeze drying is generally the preferred method for converting biopharmaceutical formulations into a solid state for long-term storage. The freeze-dried cake can preferably be stored at room temperature for a relatively long period of time. The application provides a freeze-drying method for obtaining a target percentage of residual moisture of a freeze-dried product having increased room temperature storage long-term product stability or having improved refrigerated storage stability.
[0006] A conventional method for preparing a lyophilized cake comprises placing a formulation in a chamber of a freeze dryer, such as placing the formulation in a container / vial on a shelf of a freeze drying chamber of the freeze dryer; freezing the formulation, such as at a low shelf temperature of less than -30°C; subjecting the formulation to primary drying to remove frozen solvent molecules by sublimation, wherein the primary drying is performed under high vacuum (such as a chamber pressure typically less than 200 mTorr) at a shelf temperature of the freeze dryer, which is a relatively low shelf temperature, for example, typically at or below about 0°C; and subjecting the formulation to secondary drying to remove desorbed solvent molecules to obtain a target weight percentage of the solvent molecules in the lyophilized cake, wherein the secondary drying is performed under high vacuum (such as a chamber pressure less than 200 mTorr) at a relatively high shelf temperature of 25°C or above.
[0007] The present disclosure provides a method for preparing a lyophilized cake, the method comprising: preparing a formulation, wherein the formulation comprises at least one solvent molecule and a peptide or protein; subjecting the formulation to lyophilization to obtain the lyophilized cake, comprising: (a) placing the formulation in a chamber of a freeze dryer, such as placing the formulation in a container / vial on a shelf of a freeze drying chamber of the freeze dryer; (b) freezing the formulation; (c) subjecting the formulation to a first drying, e.g., a primary drying, to remove at least one frozen solvent molecule by sublimation, wherein the first drying is performed at a shelf temperature of the freeze dryer at or below about 0° C.; and (d) subjecting the formulation to a second drying, e.g., a secondary drying, to remove the at least one solvent molecule to obtain a target weight percentage of the at least one solvent molecule in the lyophilized cake, wherein the second drying is performed at the shelf temperature of the freeze dryer at or below about 0° C. In some embodiments, there is no distinct secondary drying. In some exemplary embodiments, the target weight percentage of the at least one solvent molecule in the lyophilized cake is about 3%-5%, about 4%, or about 4.5%.
[0008] In some exemplary embodiments, the at least one solvent molecule in the formulation is a water molecule. In some exemplary embodiments, the peptide or protein in the formulation of the present application is an antibody, an antibody fragment, an antibody Fab region, an antibody-drug conjugate, a fusion protein, a protein pharmaceutical product or a drug. In some exemplary embodiments, the lyophilized cake produced using the method of the present application is stable under storage conditions at room temperature or has improved refrigerated storage stability.
[0009] In some aspects, the target weight percentage of the at least one solvent molecule in the lyophilized cake of the present application is controlled by the shelf temperature of the freeze dryer for performing the second drying at a controlled drying rate. In some aspects, the target weight percentage of the at least one solvent molecule in the lyophilized cake of the present application is controlled by the duration of the second drying.
[0010] In some aspects, the shelf temperature of the freeze dryer for the second drying, e.g., secondary drying, is the same as the shelf temperature of the freeze dryer for the first drying, e.g., primary drying. In some aspects, the shelf temperature of the freeze dryer for the second drying may be higher than the shelf temperature of the freeze dryer for the first drying. In some aspects, the shelf temperature of the freeze dryer for the second drying may be lower than the shelf temperature of the freeze dryer for the first drying. In some aspects, the shelf temperature of the freeze dryer for the second drying is equal to or slightly higher than the shelf temperature of the freeze dryer for the first drying.
[0011] In some aspects, the method of the present application further comprises determining the end of the first drying based on the change in pressure in the chamber of the freeze dryer. In some aspects, the temperature of the freeze-dried cake is lower than the collapse temperature of the freeze-dried cake in the first drying.
[0012] In some exemplary embodiments, the formulation of the present application further comprises a buffer, an excipient, a stabilizer, a cryoprotectant, a filler, a plasticizer, or a combination thereof; wherein the stabilizer is a polyol, sucrose, mannitol, trehalose, sorbitol, an amino acid, or a combination thereof; wherein the cryoprotectant is a surfactant, a sugar, a salt, an amino acid, or a combination thereof. In some aspects, the buffer comprises acetate and / or histidine hydrochloride, the pH value of the buffer is about 5.3 or about 6, and the excipient is polysorbate 80. In some aspects, the stabilizer is sucrose, wherein the ratio of sucrose to the peptide or the protein is about 1:1, about 3:1, about 10:1, or about 1:1 to 10:1.
[0013] When considered in conjunction with the following description and the accompanying drawings, these and other aspects of the present invention will be better appreciated and understood. The following description, although showing various embodiments and numerous specific details thereof, is provided by way of illustration and not limitation. Within the scope of the present invention, many substitutions, modifications, additions or rearrangements may be made. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1The results of chamber pressure measurements in the freeze drying process taught by Patel et al. are shown. According to Patel et al., the chamber pressure measured by a capacitance manometer, the chamber pressure measured by a Pirani gauge, and the chamber pressure set point (Vac SetPt) are plotted against the drying time.
[0015] Figure 2 A conventional freeze-drying method comprising three steps, e.g., freezing, primary drying, and secondary drying is shown. Conventional freeze-drying is performed in three steps, comprising: freezing at a shelf temperature of about -45°C; primary drying at a shelf temperature of about -20°C or about -25°C; and secondary drying at a higher temperature, such as at a shelf temperature of about 40°C. Conventionally, the secondary drying shelf temperature, such as about 40°C, is always significantly higher than the primary drying shelf temperature, such as about -20°C or -25°C.
[0016] Figure 3 The unique freeze drying method of the present application is shown by performing secondary drying at a controlled desorption rate to achieve a target percentage of residual solvent according to an exemplary embodiment. According to an exemplary embodiment, the secondary drying of the present application is considered to be an extension of the primary drying, and the secondary drying is: performed at a lower temperature such as the same temperature as the shelf temperature of the primary drying; performed at a temperature slightly higher than the shelf temperature of the primary drying; or performed at a temperature lower than the shelf temperature of the primary drying. In some aspects, there is no obvious secondary drying.
[0017] Figure 4 The difference between the measurement results using a Pirani gauge (PG) and the measurement results using a capacitance manometer (CM) (e.g., PG-CM) is shown as an indicator of distinct endpoints of primary drying, e.g., start, midpoint, and cutoff, which indicates the completion of ice sublimation in a freeze-drying method according to Patel et al. and exemplary embodiments. According to Patel et al. and exemplary embodiments, the measurement results of PG-CM corresponding to the relevant residual moisture percentage in the sample are indicated in the figure.
[0018] Figure 5 The desorption rate after sublimation is completed according to an exemplary embodiment is shown. According to an exemplary embodiment, secondary drying is performed at the same shelf temperature as the primary drying by extending the primary drying with a shelf temperature of 0°C, -10°C, -20°C or -30°C. In some aspects, there is no significantly different secondary drying.
[0019] Figure 6 Shown are glass transition temperatures of lyophilized protein formulations corresponding to residual moisture content percentages, including recommended storage temperatures, according to exemplary embodiments.
[0020] Figure 7The measurement results of chamber pressure in a freeze drying process using an extended duration measured by a capacitance manometer (CM) and a Pirani gauge (PG) according to an exemplary embodiment are shown. The chamber pressure is plotted as a function of drying time according to an exemplary embodiment. According to an exemplary embodiment, the difference between PG and CM, e.g., (PG-CM), is used to determine the cutoff point for initial drying.
[0021] Figure 8 Desorption rates with extended primary drying duration at shelf temperatures of -20°C or -30°C after ice sublimation is complete are shown according to an exemplary embodiment. According to an exemplary embodiment, the moisture content obtained is plotted as a function of duration from cutoff. DETAILED DESCRIPTION
[0022] Lyophilization is a common method for preparing and manufacturing protein drugs. Lyophilization, for example, freeze drying, can be used to remove ice or other freezing solvents from protein formulations by sublimation, and to remove bound water molecules by desorption. There are various challenges in selecting key process parameters to develop lyophilization methods. Conventional lyophilization of protein formulations can be carried out in three steps, for example, freezing, primary drying (sublimation) and secondary drying (desorption), such as freezing at about -45°C, primary drying at about -20°C, and secondary drying at about 40°C, about 35°C-55°C or about 25°C-55°C. Due to the presence of bound water molecules connected to the product, the dried product of the protein formulation after completing the primary drying can still have a moisture content of about 5%-10%. Conventional secondary drying is usually carried out at a temperature much higher than the temperature of the primary drying to achieve a residual moisture content of less than about 1% or about 2%, such as drying at about 40°C, about 35°C-55°C or about 25°C-55°C.
[0023] The present application provides a unique freeze-drying method that is very different from a conventional freeze-drying method. For example, the present application provides a unique freeze-drying method for achieving a target weight percentage of about 4.0%, about 4.5% or about 3%-5% residual moisture by performing secondary drying at a controlled desorption rate. The secondary drying of the present application can be considered as an extension of the primary drying, and the secondary drying can be performed at a controlled desorption rate at a temperature that is the same as the shelf temperature of the primary drying, at a temperature slightly higher than the shelf temperature of the primary drying, or at a temperature lower than the shelf temperature of the primary drying. On the one hand, the shelf temperature of the freeze dryer for the second drying is equal to or slightly higher than the shelf temperature of the freeze dryer for the first drying. Alternatively, the freeze drying can be performed without a significantly different secondary drying step. The freeze drying of the present application is very different from conventional freeze drying because the secondary drying of the present application can be performed at a lower temperature that is much lower than the temperature of conventional secondary drying.
[0024] There are various challenges in selecting key process parameters to develop a freeze-drying method, for example, performing freezing, primary drying and secondary drying. The key process parameters for freeze-drying are mainly determined by the physicochemical properties of the product formulation, such as the collapse temperature and / or the frozen state glass transition temperature (Tg′) of the product formulation. By maintaining the product temperature at a favorable low temperature during the freezing and primary drying stages, the drying process can be well controlled during the freeze-drying process to avoid changes in the appearance and characteristics of the dried product. For example, during the freeze-drying method, the drying process of each process stage, including shelf temperature, chamber pressure, duration and heating rate, can be well controlled. The present application provides a method for achieving a target moisture content in a freeze-dried product by controlling the shelf temperature and duration for secondary drying.
[0025] The freezing step of the freeze-drying method comprises freezing the product formulation to produce a solid matrix for drying. Sometimes, the freezing step may include an additional annealing step (Chang et al.) or a controlled nucleation step (Fang et al., Effect of Controlled Ice Nucleation on Stability of Lactate Dehydrogenase During Freeze-Drying, JPharm Sci., March 2018, 107(3): 824-830). The initial drying step of the freeze-drying method comprises removing the freezing solvent, such as ice, by sublimation at reduced pressure while maintaining the product temperature at a low target level. The sublimation process refers to the process in which a substance is directly converted from a solid phase (such as ice) to a gas phase (such as steam) without passing through a liquid phase (such as water). Low pressure is generally required for sublimation to occur. Sublimation, for example, an endothermic process, occurs at a temperature and pressure below the triple point of the substance in a phase diagram, the pressure corresponding to the minimum pressure at which the substance can exist in liquid form. In addition, since sublimation is an endothermic phase change, it is necessary to add thermal energy to the frozen material, which is provided by controlling the freeze-drying shelf temperature above the product temperature during the primary drying. The product temperature is controlled to be several degrees below the collapse temperature (or Tg') by controlling both the shelf temperature and the chamber pressure. The secondary drying step of the freeze-drying process involves removing bound water by desorption to achieve a desired residual moisture content at a target level. During the drying process, the condenser is controlled at a low temperature, for example, below -50°C and under low pressure to effectively convert and capture the sublimated solvent in the solid state.
[0026] The freeze drying equipment may include a refrigeration system, a vacuum system, a control system, a product chamber, and a condenser. The shelf temperature of the product chamber of the freeze dryer needs to be properly controlled for primary drying and secondary drying. During the primary drying step of the freeze drying process, the chamber pressure of the freeze dryer can be reduced to a saturated vapor pressure below the refrigerated solvent at the temperature of the frozen product by introducing a vacuum. The primary drying step can be considered complete when all or substantially all of the refrigerated solvent is removed by sublimation. If there is still bound unfrozen solvent in the product formulation after the primary drying step is completed, then during the secondary drying of a conventional freeze drying process, these bound unfrozen solvents can be removed by desorption at a much higher temperature. (Chang et al.)
[0027] The apparent end point of primary drying (sublimation), e.g., the start, midpoint, and cutoff of the PG (Pirani gauge) chamber pressure, can be determined by various methods, such as comparative pressure measurements (Pirani gauge vs. capacitance manometer), dew point, gas plasma spectroscopy, water vapor concentration, condenser pressure, boost test, or product thermocouple (Patel et al., Determination of end point of primary drying in freeze-drying process control, AAPS PharmSciTech, Vol. 11, No. 1, March 2010). The Pirani gauge measures the thermal conductivity of the gas in the chamber. During freeze drying, a capacitance manometer that measures the absolute pressure in the chamber can be used to control the chamber pressure. When essentially all of the gas in the chamber is water vapor, the Pirani gauge reading during primary drying is about 60% higher than the capacitance manometer because the thermal conductivity of water vapor is about 1.6 times that of nitrogen. When the Pirani pressure begins to drop sharply, e.g., the starting point, it indicates that the gas composition changes from primarily water vapor to primarily nitrogen, which can indicate the end of primary drying (Patel et al.). For example, changes in PG chamber pressure can be related to moisture content. The chamber pressure measured by the capacitance manometer, the chamber pressure measured by the Pirani gauge, and the chamber pressure set point (VacSetPt) are plotted against the drying time, as shown in Figure 1 As shown (according to Patel et al. Figure 7 ). The percentage of residual moisture is measured by gravimetric method and / or Karl Fischer method.
[0028] Typically, the freeze-drying process involves three steps, e.g., freezing, primary drying, and secondary drying at a higher temperature. Figure 2As shown, conventional freeze drying can be performed in three steps, including freezing at a shelf temperature of about -45°C for at least about 120 minutes, primary drying at a shelf temperature of about -20°C for about 1-3 days, and secondary drying at a higher temperature (such as about 40°C). In conventional freeze drying methods, a large amount of water can be removed by sublimation under vacuum during the primary drying at low temperature, such as in the range of a shelf temperature of about -10°C to about -35°C or a shelf temperature of about -40°C to about -45°C. During the secondary drying, the bound unfrozen water remaining in the product can be removed by rapid desorption at a high temperature (such as at a shelf temperature of about 40°C), such as Figure 2 Typically, by applying conventional secondary drying at elevated temperatures, the residual moisture content of the freeze-dried product can be reduced to less than about 1%. Typically, the residual moisture content of the freeze-dried product can be reduced by increasing the shelf temperature and the duration of the secondary drying.
[0029] The present application provides a unique freeze-drying method that is significantly different from conventional freeze-drying methods by performing secondary drying at a controlled desorption rate to achieve a target percentage of residual solvent. In some embodiments, there is no significant difference in secondary drying. In some exemplary embodiments, the secondary drying of the freeze-drying method of the present application can be performed at a controlled desorption rate to achieve a target weight percentage of residual moisture in the freeze-dried product, such as about 4.0%, about 4.5%, or about 3%-5%. In some aspects, the secondary drying of the freeze-drying method of the present application can be performed at a controlled desorption rate, wherein the shelf temperature of the secondary drying in the freeze-drying method of the present application can be much lower than the shelf temperature of conventional secondary drying. For example, the secondary drying of the present application can be considered as an extension of the initial drying, and the secondary drying can be performed at a low temperature (such as about -20°C, in the range of about -10°C to about -30°C, in the range of about 0°C to about -30°C), at the same temperature as the shelf temperature of the initial drying, at a temperature slightly higher than the shelf temperature of the initial drying, or at a temperature slightly lower than the shelf temperature of the initial drying, such as Figure 3 In contrast, conventional secondary drying is performed at high temperatures (eg, about 40° C. or in the range of about 35° C. to about 55° C.).
[0030] During the initial drying period, the sublimation surface moves through the product to deposit the dried product, e.g., cake, above the ice surface interface, and sublimates ice crystals. The desired cake has an almost uniform appearance with some slight flaking or cracking along the surface or edge. Due to the presence of bound water molecules attached to the product, the dried product of the protein formulation after sublimation can have a moisture content of 5%-10%. Generally, the frozen product can be structurally classified as crystalline glass or amorphous glass. It has been found that the glass transition temperature (Tg') of the frozen product is closely related to the collapse temperature (Tc) of the freeze-dried cake during the initial drying period. The glass transition temperature can be considered as the temperature region in which the dry product is transformed from a rigid glass state to a flexible rubber state with higher fluidity. When the product temperature is maintained below Tg', the integrity of the cake structure can be maintained in a glassy state, where fluidity can be ignored. It is important to maintain the product temperature below the Tg' of the protein formulation during the initial drying period to prevent the cake from collapsing. (Chang et al.) When the cake becomes soft, the cake structure is usually not maintained.
[0031] It is expected that there is no sign of collapse or melt-back of the cake during freeze drying. The expected good cake has a rigid macrostructure and should not have collapse, discoloration and melt-back. The collapse (or partial collapse) of the cake may be due to the eutectic melting of the crystallizing agent (at the ice sublimation interface) in the product formulation during the initial drying. It is expected that the product temperature will be kept below the eutectic melting temperature of the crystalline component of the product formulation during the initial drying. (Chang et al.) The melting back of the cake can be considered as a form of partial or complete cake collapse caused by incomplete sublimation of ice during the initial drying. The product temperature is related to the vapor pressure at the ice sublimation interface. The vapor pressure depends on the heat transfer rate of the product controlled by the set point of the shelf temperature and the system vacuum. By controlling the shelf temperature and the system vacuum (pressure) during the initial drying, the target product temperature can be properly maintained.
[0032] In one embodiment, the method includes a step of obtaining an aqueous sample containing a protein and an excipient in a container. The container can be a vial, a glass vial, a syringe barrel, or a chamber of a dual-chamber automatic syringe. The container can be fully opened to allow the release of water vapor. The container containing the aqueous sample is placed in the chamber, and heat can be removed from the sample to reach a first temperature, wherein ice crystals are formed in the sample. Air can be removed from the chamber to obtain a first pressure. Thermal energy can then be added to the sample to obtain a second temperature, thereby permitting the removal of water from the sample by sublimation. Residual water after sublimation may be embedded in the sample, and the residual water can be removed by a second drying step. On the one hand, during the initial freezing and preliminary drying steps, heat can be removed from the aqueous sample at a rate of about 0.5°C per minute. On the one hand, the first temperature is about -45°C.
[0033] Excipients are ingredients added with the active drug substance in a pharmaceutical formulation. Excipients can help stabilize the drug substance and / or increase the volume of the formulation. The term ingredient can be used interchangeably with excipient. Excipients include various materials for various purposes such as buffering, swelling, solubilizing, stabilizing, plasticizing and protecting drug substances. Protective agents can prevent thermal stress and / or physical stress, such as stirring. Cryoprotectants can protect proteins from freezing stress, such as ice interface stress and freeze concentration stress. Freeze-drying protectants can protect proteins from freezing and dehydration pressure. Excipients can include stabilizers. Stabilizers can be added to pre-freeze-dried solutions to stabilize proteins to prevent polymerization or other degradation. Stabilization can be achieved by controlling glass dynamics during the freeze-drying process or by helping to maintain the native structure of the protein through the specific interaction of stabilizers and proteins.
[0034] The need to produce biopharmaceutical formulations with long-term storage stability at room temperature has led to an increasing demand for the development of lyophilization methods. The present disclosure provides methods to meet the above needs by providing methods for lyophilizing biopharmaceutical formulations to produce lyophilized products with desired properties and residual moisture content.
[0035] Exemplary embodiments disclosed herein meet the above needs by providing a lyophilization method for achieving a target percentage of residual moisture in a lyophilized pharmaceutical product that is stable to room temperature storage or has improved refrigerated storage stability.
[0036] The terms "a" and "an" should be understood to mean "at least one"; and the terms "about" and "approximately" should be understood to allow for standard variations, as would be understood by one of ordinary skill in the art; and where a range is provided, the endpoints are included.
[0037] As used herein, the terms "include," "includes," and "including" are intended to be non-limiting and are understood to mean "comprise," "comprises," and "comprising," respectively.
[0038] In some exemplary embodiments, the present disclosure provides a method for preparing a lyophilized cake, the method comprising: preparing a formulation, wherein the formulation comprises at least one solvent molecule and a peptide or protein; subjecting the formulation to lyophilization to obtain the lyophilized cake, comprising: (a) placing the formulation in a chamber of a freeze dryer, such as placing the formulation in a container / vial on a shelf of a freeze drying chamber of the freeze dryer; (b) freezing the formulation; (c) subjecting the formulation to a first drying (primary drying) to remove at least one frozen solvent molecule by sublimation, wherein the first drying is performed at a shelf temperature of the freeze dryer at or below 0° C.; and (d) subjecting the formulation to a second drying (secondary drying) to remove the at least one solvent molecule to obtain a target weight percentage of the at least one solvent molecule in the lyophilized cake, wherein the second drying is performed at the shelf temperature of the freeze dryer at or below 0° C. Alternatively, the lyophilization may be performed without a distinct secondary drying step.
[0039] As used herein, the term "sublimation" refers to the phenomenon that water molecules (solvent molecules) change directly from a solid state (ice) to a gaseous state without passing through a liquid state in freeze drying (freeze drying). During freeze drying, the product is frozen and placed under a vacuum, allowing ice to change directly from a solid state to a gaseous state without passing through a liquid state. Sublimation is an endothermic process that occurs at a temperature and pressure lower than the triple point of a substance in a phase diagram, corresponding to the lowest pressure at which a substance can exist in liquid form. The sublimation of water can occur at a pressure and temperature (e.g., 4.579 mmHg and 0.0099 ° C) lower than the triple point. The rate at which ice sublimates from the frozen product depends on the difference in the vapor pressure of the product at the ice sublimation interface compared to the vapor pressure of the freeze drying chamber, which is usually slightly higher than or equal to the pressure of the cold trap (Nireesha et al., Lyophilization / freeze drying-an review, International Journal of Novel Trends in Pharmaceutical Sciences, pp. 87-98, Vol. 3, No. 4, October 2013; Chang et al.). The rate at which ice sublimates from the frozen product also depends on the resistance of the dry cake to vapor transfer from the ice sublimation interface.
[0040] As used herein, the term "freeze dryer" refers to a system that includes: (a) a freeze drying chamber with shelves in which filled vials are loaded for freeze drying; (b) a condenser for capturing sublimated water vapor as ice; (c) a refrigeration and heating unit to facilitate temperature control; and (d) a vacuum pump that can reduce the chamber pressure to a value below atmospheric pressure. The chamber pressure of the freeze dryer is maintained at a set value by the controlled introduction of an inert, dry exhaust gas (usually nitrogen). In most cases, the freeze drying chamber is separated from the condenser by a main valve. Product vials are loaded onto the shelves of the chamber, where the shelf temperature is controlled. (Chang et al.)
[0041] As used herein, the term "peptide" or "protein" includes any amino acid polymer with covalently linked amide bonds. Proteins include one or more amino acid polymer chains, commonly referred to in the art as "peptides" or "polypeptides". A protein may contain one or more polypeptides to form a single functional biomolecule. In some exemplary embodiments, a protein may be an antibody, a bispecific antibody, a multispecific antibody, an antibody fragment, a monoclonal antibody, a host cell protein, or a combination thereof.
[0042] In one aspect, the peptide or protein in the formulation of the present application is an antibody, an antibody fragment, an Fab region of an antibody, an antibody-drug conjugate, a fusion protein, a protein pharmaceutical product or a drug.
[0043] As used herein, the term "antibody" refers to an immunoglobulin molecule consisting of four polypeptide chains, two heavy (H) chains and two light (L) chains interconnected by disulfide bonds. Each heavy chain has a heavy chain variable region (HCVR or VH) and a heavy chain constant region. The heavy chain constant region contains three domains CH1, CH2 and CH3. Each light chain has a light chain variable region and a light chain constant region. The light chain constant region consists of a domain (CL). The VH region and the VL region can be further subdivided into hypervariable regions called complementary determining regions (CDRs), which are interspersed with more conservative regions called framework regions (FRs). Each VH and VL can be composed of three CDRs and four FRs arranged from the amino terminus to the carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The term "antibody" includes reference to glycosylated and non-glycosylated immunoglobulins of any isotype or subclass. The term "antibody" includes but is not limited to those antibodies that are prepared, expressed, produced or isolated by recombinant means, such as antibodies isolated from host cells transfected to express the antibody. IgG comprises a subset of antibodies.
[0044] As used herein, the term "antibody fragment" comprises a portion of a complete antibody, such as, for example, an antigen binding or variable region of an antibody. Examples of antibody fragments include, but are not limited to, Fab fragments, Fab' fragments, F(ab')2 fragments, Fc fragments, scFv fragments, Fv fragments, dsFv double antibodies, dAb fragments, Fd' fragments, Fd fragments, and isolated complementarity determining regions (CDR) regions, as well as tri-antibodies, tetra-antibodies, linear antibodies, single-chain antibody molecules, and multi-specific antibodies formed by antibody fragments. Fv fragments are combinations of the variable regions of immunoglobulin heavy and light chains, and ScFv proteins are recombinant single-chain polypeptide molecules in which immunoglobulin light and heavy chain variable regions are connected by peptide linkers. Antibody fragments can be produced in various ways. For example, antibody fragments can be produced enzymatically or chemically by fragmentation of complete antibodies and / or they can be produced recombinantly by genes encoding partial antibody sequences. Alternatively or additionally, antibody fragments can be produced completely or partially synthetically. Antibody fragments can optionally include single-chain antibody fragments. Alternatively or additionally, an antibody fragment may comprise multiple chains linked together, for example, by disulfide bonds.Antibody fragments may optionally comprise multimolecular complexes.
[0045] As used herein, the term "antibody-drug conjugate" or "ADC" may refer to an antibody connected to a bioactive drug by a linker having an unstable bond. ADC may include several molecules (Siler Panowski et al., Site-specific antibody drug conjugates for cancer therapy, 6 "mAbs" 34-45 (2013)) of a bioactive drug (or payload) that can be covalently linked to the side chain of an amino acid residue of an antibody. The antibody used for ADC can be combined with sufficient affinity to selectively accumulate and persist at the target site. The Kd value of most ADCs can be in the nanomolar range. The payload can have efficacy in the nanomolar / picomolar range and can reach an intracellular concentration that can be achieved after the ADC is distributed in the target tissue. Finally, the linker formed between the payload and the antibody can be sufficiently stable in the circulation to utilize the pharmacokinetic properties (e.g., long half-life) of the antibody portion and allow the payload to remain connected to the antibody when it is distributed in the tissue, however, once the ADC can be absorbed by the target cell, it should be allowed to effectively release the bioactive drug. Linkers can be: those that are not cleavable during cellular processing and those that are cleavable after the ADC reaches the target site. For non-cleavable linkers, after complete proteolytic degradation of the ADC in the lysosome, the bioactive drug released in the call contains all elements of the linker that are still connected to the amino acid residues (usually lysine or cysteine residues) of the antibody. A cleavable linker is a linker whose structure contains a cleavage site between the amino acid attachment site on the payload and the antibody. The cleavage mechanism can include hydrolysis of acid-labile bonds in acidic intracellular compartments, enzymatic cleavage of amide or ester bonds by intracellular proteases or esterases, and reductive cleavage of disulfide bonds by the reducing environment in the cell.
[0046] As used herein, the term "protein drug product" includes active ingredients that may be completely or partially biological in nature. In some exemplary embodiments, the protein drug product may include a peptide, protein, fusion protein, antibody, antigen, vaccine, peptide-drug conjugate, antibody-drug conjugate, protein-drug conjugate, cell, tissue, or a combination thereof. In some other exemplary embodiments, the protein drug product may include a recombinant, engineered, modified, mutated, or truncated form of a peptide, protein, fusion protein, antibody, antigen, vaccine, peptide-drug conjugate, antibody-drug conjugate, protein-drug conjugate, cell, tissue, or a combination thereof.
[0047] Exemplary Embodiments
[0048] Embodiments disclosed herein provide compositions and methods for performing lyophilization to achieve a target percentage of residual moisture in a lyophilized product that is stable for room temperature storage or has improved refrigerated storage stability.
[0049] In some exemplary embodiments, the present disclosure provides a lyophilized cake having a target weight percentage of at least one solvent molecule in the lyophilized cake, such as about 3%-6%, about 4%, about 4.5%, about 2%-5.5%, about 2.5%-6%, about 3%-4.5%, about 3.5%-6.5%, about 4%-5%, about 4.1%, about 4.2%, about 4.3%, about 4.4%, about 4.6%, about 4.7%, about 4.8% or about 4.9%.
[0050] In some exemplary embodiments, the shelf temperature for carrying out the second drying of the freeze dryer can be the same as the shelf temperature for carrying out the first drying (preliminary drying) of the freeze dryer. In some aspects, the shelf temperature for the second drying (secondary drying) of the freeze dryer can be slightly higher than the shelf temperature for the first drying of the freeze dryer. In some aspects, the shelf temperature for the second drying of the freeze dryer can be lower than the shelf temperature for the first drying of the freeze dryer. In some aspects, the difference between the shelf temperature for the second drying of the freeze dryer and the shelf temperature for the first drying of the freeze dryer can be about 0-25 ° C, about 0-20 ° C, about 0-15 ° C, about 0-10 ° C, about 0-5 ° C, about 0-3 ° C, about 0-2 ° C, about 1 ° C, about 2 ° C, about 3 ° C, about 4 ° C, about 5 ° C, about 6 ° C, about 7 ° C, about 8 ° C, about 9 ° C or about 10 ° C.
[0051] In some exemplary embodiments, the method of the present application further includes determining the end of the first drying (primary drying) based on the change of the PG pressure in the chamber of the freeze dryer. In some aspects, the change of the pressure in the chamber of the freeze dryer is measured by a Pirani gauge and / or a capacitance manometer. The difference between the measured values of the Pirani gauge (PG) and the capacitance manometer (CM), for example, PG-CM, is used as an indicator to define the end of the first drying or the end of the secondary drying. In some aspects, the chamber pressure of the freeze dryer can be maintained at a typical condition of about 100mTorr or other typical conditions, such as 50mTorr or 200mTorr.
[0052] In some exemplary embodiments, by placing the formulation of the present application in the chamber of a freeze dryer, the formulation is subjected to freeze drying to obtain a lyophilized cake. The formulation can be transferred to a bottle, such as a glass bottle, and then the bottle is placed in the chamber of a freeze dryer. The filling depth of the bottle is about 1cm, about 1.5cm, about 0.8cm, about 0.9cm, about 1.1cm, about 1.2cm, about 1.3cm, about 1.4cm, about 1.6cm, about 1.7cm, about 1.8cm, about 1.9cm or about 2cm. The glass bottle size is about 2mL, about 5mL, about 10mL, about 20mL, about 6mL, about 7mL, about 8mL, about 9mL, about 15mL, about 25mL, about 30mL, about 40mL or about 50mL. Loading the glass bottle to the freeze dryer can be full shelf loading or partial shelf loading.
[0053] In some exemplary embodiments, the formulation of the present application further includes a buffer, an excipient, a stabilizer, a cryoprotectant, a lyoprotectant, a filler, a plasticizer, or a combination thereof; wherein the stabilizer is a polyol, sucrose, mannitol, trehalose, sorbitol, an amino acid, or a combination thereof; wherein the cryoprotectant or lyoprotectant is a surfactant, a sugar, a salt, an amino acid, or a combination thereof. In some aspects, the buffer comprises acetate or histidine hydrochloride, the pH value of the buffer is about 5.3, and the excipient is polysorbate 80. In some aspects, the stabilizer can be sucrose, wherein the ratio of sucrose to peptide or protein is about 1:1, such as containing 50 mg / mL sucrose and 50 mg / mL protein. Some formulations include sucrose and protein at a ratio of about 1:1, about 3:1, about 10:1, or about 1:1 to 10:1. In some aspects, the stabilizer comprises glycerol, mannitol, trehalose, sorbitol, sucrose, arginine hydrochloride, alanine, proline, glycine, sodium chloride or a combination thereof. In some aspects, the stabilizer accounts for about 19.9% to about 82.2% of the weight of the freeze-dried cake. In some aspects, the stabilizer is sucrose, and according to the presence of other stabilizer components and the amount of protein, water and other excipients, the stabilizer accounts for about 3% to about 15% of the weight of the freeze-dried cake, preferably about 5%-11%, 4%-7.5% or 5%-7.5%. On the one hand, the weight ratio of protein to stabilizer is between 1:1-3:1, preferably 1.2:1-2:1, more preferably about 1.5:1. In some aspects, the excipient includes a surfactant, such as about 0.01% to about 0.96% of a surfactant. The surfactant can include a nonionic detergent, such as a fatty acylated polyethoxylated dehydrated sorbitan. In some aspects, a pharmaceutically acceptable lyophilized cake is prepared from a previously lyophilized aqueous solution, e.g., a protein formulation, prepared by combining protein, buffer, nonionic surfactant, and one or more stabilizers in water. The solution is then freeze-dried to prepare a cake containing a desired target residual moisture content.
[0054] It should be understood that the method is not limited to any of the above-mentioned lyophilization methods, formulations, freeze dryers, pressure measurement methods, pharmaceutical products, peptides, proteins or antibodies. The method steps marked consecutively with numbers and / or letters as provided herein are not meant to limit the method or any embodiment thereof to a specific indicated order.
[0055] Various publications are cited throughout the specification, including patents, patent applications, published patent applications, accession numbers, technical articles and academic articles. Each of these cited references is incorporated herein by reference in its entirety and for all purposes. Unless otherwise described, all technical terms and scientific terms used herein have the same meaning as those commonly understood by those of ordinary skill in the art to which the invention belongs.
[0056] The present disclosure will be more fully understood by reference to the following examples, which are provided to describe the present disclosure in more detail. The examples are intended to illustrate and should not be construed as limiting the scope of the present disclosure.
[0057] Examples
[0058] method
[0059] 1. Determination of residual moisture
[0060] According to Patel et al., the percentage of residual moisture in the sample during freeze drying is determined using either the gravimetric method or the Karl Fischer method. The vial containing the freeze-dried sample is retrieved using a sampler. If the selected sample vial completely melts back after warming to room temperature due to the presence of residual ice, the residual moisture is calculated gravimetrically. If the selected sample vial retains a cake structure, the residual moisture is determined using a Karl Fischer residual moisture analyzer. In some embodiments of the present application, in order to retrieve the vial containing the freeze-dried sample, the freeze-drying run is stopped to retrieve the sample. Subsequently, the freeze-drying run is restarted. In some embodiments of the present application, a Vapor is used. A moisture analyzer (Arizona Instrument LLC) analyzes the percentage of residual moisture in the sample. The sample is heated in a Vapor Pro moisture analyzer and the released volatiles are passed to an analysis unit for measuring the moisture content of the flowing gas to be converted to total water to calculate the water percentage.
[0061] Example 1. Determination of the completion of primary drying
[0062] Previous studies were conducted to investigate product stability of lyophilized protein formulations. The results indicated that lyophilized products containing about 0% moisture content had relatively low stability, with higher amounts of high molecular weight (HMW) aggregates formed. Lyophilized products containing about 3%-5% moisture content had higher stability, with lower amounts of HMW aggregates. The target residual moisture content of lyophilized products for optimal stability under storage conditions of 25° C. was estimated to be about 4.0%, about 4.5%, or about 3%-5%.
[0063] In order to achieve a target residual moisture content of about 4.0%, about 4.5%, or about 3%-5% for the lyophilized product to achieve optimal stability under storage conditions at 25°C, the completion of primary drying, e.g., sublimation, is determined during the lyophilization process. According to Patel et al., Figure 4As shown, the apparent endpoints of preliminary drying, e.g., start, midpoint, and cutoff, are determined by the measurements of the Pirani gauge at different time points during the preliminary drying time. According to Patel et al., the distribution of the percentage of residual water from incomplete ice sublimation is related to the chamber pressure measured by the Pirani gauge and / or the capacitance manometer. The difference between the measurements of the Pirani gauge (PG) and the capacitance manometer (CM), e.g., PG-CM, is used as an indicator to define a global cutoff point that indicates the completion of sublimation (preliminary drying) during the freeze-drying process. Experiments were performed using protein formulations containing 5% sucrose or 5% mannitol. As Figure 4 As shown, the measurement result of PG-CM corresponding to the starting point has about 25% residual moisture in the sample. Figure 4 As shown, the measurement result of PG-CM corresponding to the midpoint has about 9% residual moisture in the sample. Figure 4 As shown, when the sublimation of ice in the sample is completely completed, the PG-CM measurement corresponding to the cut-off point has about 5% residual moisture. The protein formulation containing 5% sucrose has about 5% residual moisture at the cut-off point. The protein formulation containing 5% mannitol has about 4% residual moisture at the cut-off point.
[0064] Example 2. Development of a freeze-drying process to achieve a target residual moisture content
[0065] In order to achieve a target residual moisture content of about 3%-5% for the freeze-dried product, various experimental parameters of the freeze-drying process were tested. Various shelf temperatures for primary drying were tested, such as 0°C, -10°C, -20°C or -30°C. Secondary drying (or an extension of primary drying) was performed after sublimation (e.g., primary drying) was completed. Several shelf temperatures for secondary drying, such as 0°C, -10°C, -20°C, -30°C, were tested to study changes in desorption rates during secondary drying. The shelf temperature for secondary drying in the experimental design of the present application is significantly lower than the shelf temperature for conventional secondary drying, because conventional secondary drying is typically performed at a higher temperature to achieve a residual moisture content of less than about 1% or about 2%, such as about 40°C, about 35°C-55°C, or about 25°C-55°C. In contrast, in order to achieve a slower desorption rate, the secondary drying of the present application is performed at the same temperature as the shelf temperature for primary drying, slightly higher than the shelf temperature for primary drying, or lower than the shelf temperature for primary drying, such as Figure 3 shown.
[0066] The chamber pressure of the freeze dryer is maintained under typical conditions of about 100mTorr. Various protein formulations were tested, including protein formulations containing sucrose at a ratio of 1:1 between protein and sucrose, such as containing 50mg / mL protein and 50mg / mL sucrose. The filling depth of the glass vial was about 1cm, such as 2.5mL filled in a 5mL glass vial. A controlled nucleation step is used during the freezing stage of the freeze-drying process, because how the product is frozen will affect its subsequent drying behavior and the quality attributes of the final product. Controlled nucleation can promote rapid crystallization, such as forming larger ice crystals. Large ice crystals can impose lower resistance to the flow of water vapor from the ice sublimation interface to reduce the time required for initial drying. Additionally, controlling nucleation during freezing results in less variability within and between batches. Vials are taken out at different time points for analysis, including checking the appearance, moisture content, and glass transition temperature of the cake. Protein formulations containing MABB (a monoclonal antibody) were used for lyophilization, such as a formulated drug substance comprising 50 mg / mL MABB, 10 mM acetate, 25 mM arginine hydrochloride, 0.2% polysorbate 80, and 5% sucrose (pH 5.3). The ratio of sucrose to protein was 1:1.
[0067] By prolonging the primary drying, secondary drying was performed at the same shelf temperature as the primary drying. Shelf temperatures of 0°C, -10°C, -20°C and -30°C were tested. The desorption rate after sublimation was completed was analyzed by determining the percentage of residual water at different time points, e.g. Figure 5 As shown. The residual water percentage corresponding to different drying time points shows an exponential decay curve. As the drying time increases, the residual water content decreases at a rate proportional to its current rate. The final decay reaches a plateau close to a constant value. When the shelf temperature is maintained at -30 ° C, the decay of the residual water content reaches a plateau close to 3.5%, which is within the target weight percentage range of 3%-5% residual moisture, as shown in Figure 5 As the final values were within the target percentage range, the drying time could be extended without further reduction in moisture content at a shelf temperature of -30°C.
[0068] like Figure 5As shown, when the shelf temperature is maintained at -20°C, the decay of the residual water content reaches a plateau close to 2.5%, which is outside the target weight percentage range of residual moisture of 3%-5%. When the shelf temperature is maintained at -10°C, the decay of the residual water content reaches a plateau close to 2.1%, which is outside the target weight percentage range of residual moisture of 3%-5%. When the shelf temperature is maintained at 0°C, the decay of the residual water content reaches a plateau close to 1.2%, which is outside the target weight percentage range of residual moisture of 3%-5%. Therefore, for higher shelf temperatures, such as -20°C, -10°C or 0°C, it is necessary to control the drying time to achieve the target weight percentage of residual moisture of 3%-5%. The drying time to achieve the target moisture content in the freeze-dried product at a given shelf temperature can be calculated by the exponential decay equation when the desorption rate at the shelf temperature is known. When the shelf temperature is relatively high, the drying time after sublimation is completed is relatively short to fully reduce the moisture content to the target percentage by controlling the desorption rate.
[0069] Example 3. Product glass transition temperature
[0070] The glass transition temperature (Tg) of the lyophilized protein formulations corresponding to the residual moisture percentage was analyzed. A protein formulation containing 50 mg / mL MABB (a monoclonal antibody), 5% sucrose, 25 mM arginine hydrochloride, 10 mM acetate, and 0.2% polysorbate 80 (pH 5.3) was lyophilized. Figure 6 As shown, Tg decreases significantly as the residual moisture percentage increases. The recommended storage temperatures are: below 52°C for 2.5% residual moisture, below 43°C for 3.3% residual moisture, below 42°C for 3.6% residual moisture, below 33°C for 4.9% residual moisture, and below 25°C for 6.6% residual moisture. For room temperature storage products, the moisture content of this formulation is preferably not higher than 5%.
[0071] Example 4. Appearance of freeze-dried cake
[0072] Various freeze drying cycles were tested to check the appearance of the freeze dried cake. It is expected that there is no sign of collapse or re-melting of the cake during freeze drying. The re-melting of the cake may be due to eutectic melting of the crystallizing agent in the product formulation at the ice sublimation interface during the initial drying period. The re-melting of the cake can be considered as a form of partial or complete cake collapse caused by incomplete sublimation of ice during the initial drying period. The desired cake has an almost uniform appearance with some slight flaking or chipping along the surface or edges.
[0073] Six different lyophilization cycles were tested using a primary drying shelf temperature of -20°C or -30°C as shown in Table 1. Protein formulations containing MABB (a monoclonal antibody) were used for lyophilization using a formulated drug substance comprising 50 mg / mL MABB, 10 mM acetate, 25 mM arginine hydrochloride, 0.2% polysorbate 80, and 5% sucrose (pH 5.3). The ratio of sucrose to protein was 1:1.
[0074] Table 1. Initial drying conditions
[0075]
[0076] The chamber pressure of the freeze dryer is maintained under typical conditions of about 100 mTorr. A controlled nucleation step at -5°C is used during the freezing phase of the freeze drying process. The chamber pressure of the freeze dryer is measured by a Pirani gauge and a capacitance manometer. The difference between the measurements of the Pirani gauge (PG) and the capacitance manometer (CM), e.g., PG-CM, is used as an indicator of the global endpoint of complete sublimation (primary drying) during the freeze drying process.
[0077] When the desired absolute pressure difference, e.g., PG-CM, is met, the initial drying in the freeze-drying process is completed. The test results are shown in Table 2. When the difference (PG-CM) is large (15 mTorr or more), the cakes of cycles 1 and 6 show a form of remelting, which indicates that ice exists due to incomplete sublimation. When the difference (PG-CM) is small (5 mTorr or less), the cakes of cycles 2-5 show the appearance of a good cake, e.g., no collapse, discoloration, and remelting, which indicates that ice sublimation is complete. After sublimation is complete, the residual moisture content percentage of the freeze-dried product is used to simulate the desorption rate curve.
[0078] Table 2. Test absolute pressure difference
[0079]
[0080] Example 5. Long-duration freeze-drying process
[0081] Freeze drying cycles with longer duration and higher number of vials were tested using a shelf temperature of -20°C. Protein formulations containing MABB (a monoclonal antibody) were used for freeze drying using a formulated drug substance comprising 50 mg / mL MABB, 10 mM acetate, 25 mM arginine hydrochloride, 0.2% polysorbate 80, and 5% sucrose (pH 5.3). The ratio of sucrose to protein was 1:1. The fill depth of the glass vials was about 1 cm, such as 2.5 mL filled in a 5 mL glass vial. Twenty-seven vials were tested. The chamber pressure of the freeze dryer was maintained under typical conditions of about 100 mTorr.
[0082] The end point of primary drying (sublimation) depends on the load. Figure 7 As shown, for example, when the (PG-CM) value reaches 2, sublimation ends, and the PG pressure curve shows a cutoff transition, and the initial drying is completed. After sublimation is completed, the residual moisture content gradually decreases, reaching the target weight percentage of residual moisture of 3%-5%, such as 4.3% or 3.8%. Figure 7 When the freeze drying process was continued for a longer duration, the residual moisture content did not decrease significantly and was still within the acceptable range of 3%-5%. When the duration of freeze drying was extended to several days, the residual moisture content reached 2.5%.
[0083] The desorption rate after sublimation is complete is analyzed using a shelf temperature of -20°C or -30°C. Figure 8 As shown, at a shelf temperature of -30°C, the moisture content (Y axis) after sublimation (primary drying) is completed reaches 9%. Secondary drying (desorption) (or extended primary drying) is achieved by controlling the desorption rate at a shelf temperature of -30°C and for an extended duration, such as 50 hours, 100 hours, 150 hours or more, as Figure 8 The X-axis indicates, for example, the time from the cutoff point of the PG pressure curve (end of ice sublimation). At a shelf temperature of -30°C for a duration of from about 30 hours to 150 hours or more, the residual moisture content obtained is within the range of the target weight percentage of residual moisture of 3% to 5%. Figure 8 As shown, at a shelf temperature of -20°C, the moisture content after sublimation (primary drying) is 7%. Secondary drying (desorption) is performed by controlling the desorption rate at a shelf temperature of -20°C and for an extended duration, such as 50 hours, 100 hours, 150 hours or more, such as Figure 8 The X-axis indicates, for example, the time from the cutoff point (end of ice sublimation) of the PG pressure curve. The residual moisture content obtained within a duration of 50 hours at a shelf temperature of -20°C is within the target weight percentage range of 3%-5% residual moisture. In the case of an extended duration of up to 150 hours or more at a shelf temperature of -20°C, the residual moisture content obtained is slightly lower than the target percentage of residual moisture content, indicating that the desorption time should be controlled within 50 hours at a shelf temperature of -20°C, preferably between 10 hours and 30 hours.
[0084] The design of experiments (DOE) for developing lyophilization was performed as shown in Table 3. Protein concentrations of 5%-15% were tested. Sucrose concentrations of 0%-5% were tested. Arginine HCl concentrations of 0%-2% were tested.
[0085] Table 3. Experimental Design (DOE)
[0086] protein% Buffer sucrose% Arginine hydrochloride % Notes 5%(50mg / mL) X mM Y buffer 0 0 Protein and buffer only 5%(50mg / mL) X mM Y buffer 5 0 5%(50mg / mL) X mM Y buffer 0 2 5%(50mg / mL) X mM Y buffer 5 2 10%(100mg / mL) X mM Y buffer 2.5 1 DOE midpoint 15%(150mg / mL) X mM Y buffer 0 0 Protein and buffer only 15%(150mg / mL) X mM Y buffer 5 0 15%(150mg / mL) X mM Y buffer 0 2 15%(150mg / mL) X mM Y buffer 5 2
Claims
1. A method for preparing a freeze-dried cake, the method comprising: preparing a formulation, wherein the formulation comprises at least one solvent molecule and a peptide or protein; Subjecting the formulation to lyophilization to obtain the lyophilized cake comprises: placing the formulation in a chamber of a freeze dryer; Freezing the formulation; subjecting the formulation to a first drying to remove at least one frozen solvent molecule by sublimation, wherein the first drying is performed at a shelf temperature of the freeze dryer at or below about 0°C; and The formulation is subjected to a second drying to remove the at least one solvent molecule to obtain a target weight percentage of the at least one solvent molecule in the lyophilized cake, wherein the second drying is performed at the shelf temperature of the freeze dryer at or below 0°C.
2. The method of claim 1, wherein the target weight percentage of the at least one solvent molecule in the lyophilized cake is controlled by the shelf temperature of the freeze dryer for performing the second drying at a controlled drying rate. 3 . The method of claim 1 , wherein the target weight percentage of the at least one solvent molecule in the lyophilized cake is controlled by a duration of the second drying. 4 . The method of claim 1 , wherein the shelf temperature of the freeze dryer for the second drying is the same as the shelf temperature of the freeze dryer for the first drying. 5 . The method of claim 1 , wherein the shelf temperature of the freeze dryer for the second drying is higher than the shelf temperature of the freeze dryer for the first drying. 6 . The method of claim 1 , wherein the shelf temperature of the freeze dryer for the second drying is lower than the shelf temperature of the freeze dryer for the first drying.
7. The method of claim 1, wherein the target weight percentage of the at least one solvent molecule in the lyophilized cake is about 3%-5%.
8. The method of claim 7, wherein the target weight percentage of the at least one solvent molecule in the lyophilized cake is about 4% or about 4.5%.
9. The method according to claim 1, wherein the peptide or the protein is an antibody, an antibody fragment, a Fab region of an antibody, an antibody-drug conjugate, a fusion protein, a protein pharmaceutical product or a drug.
10. The method of claim 1, wherein the lyophilized cake is stable under storage conditions at room temperature or has improved refrigerated storage stability.
11. The method of claim 1, wherein the at least one solvent molecule is a water molecule.
12. The method of claim 1, further comprising determining an end of the first drying based on a change in pressure in the chamber of the freeze dryer. 13 . The method of claim 1 , wherein the temperature of the lyophilized cake is lower than a collapse temperature of the lyophilized cake in the first drying.
14. The method of claim 1, wherein the formulation further comprises a buffer, an excipient, a stabilizer, a cryoprotectant, a filler, a plasticizer, or a combination thereof.
15. The method of claim 14, wherein the buffer comprises acetate and / or histidine hydrochloride.
16. The method of claim 14, wherein the pH of the buffer is about 5.3 or about 6.
17. The method of claim 14, wherein the excipient is polysorbate 80.
18. The method of claim 14, wherein the stabilizer is sucrose, wherein the ratio of sucrose to the peptide or the protein is about 1:1 to 10:
1.
19. The method of claim 18, wherein the ratio of sucrose to the peptide or the protein is about 1:1, about 3:1, or about 10:
1.
20. The method of claim 14, wherein the stabilizer is a polyol, sucrose, mannitol, trehalose, sorbitol, an amino acid, or a combination thereof.
21. The method of claim 14, wherein the cryoprotectant is a surfactant, a sugar, a salt, an amino acid, or a combination thereof.
